Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 79, 2007, Pages 2073-2077

  Hotta, Naoki ^a   Ayada, Minoru ^a   Sato, Ken ^a   Ishikawa, Tetsuya ^a   Okumura, Akihiko ^a   Matsumoto, Eiji ^a   Ohashi, Tomohiko ^a   Kakumu, Shinichi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatocellular carcinoma; Prevention; Recurrence; Vitamin K2

Indexed keywords

CISPLATIN; IOPAMIDOL; MENATETRENONE;

ABDOMINAL ANGIOGRAPHY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER INCIDENCE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; COMBINED MODALITY THERAPY; FEMALE; HEMOSTATICS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; VITAMIN K 2;

EID: 37749011807     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 35:S74-83.
2. Johnson PJ: Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51:459-462.
3. Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, et al: Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer 1993; 71:19-25.
4. Pompili M, Rapaccine GL, Covino M, Pignataro G, Caturelli E, Siena DA, et al: Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection. Cancer 2001; 92:126-135.
5. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228-232.
6. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al: Effects of long-term postoperative interferon-α therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. Ann Intern Med 2001; 134:963-967.
7. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, et al: Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138:299-306.
8. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki TT, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334:1561-1567.
9. Sheater MJ: Vitamin K. Lancet 1995; 345:229-234.
10. Wang Z, Wang M, Finn F, Carr BI: The growth inhibitory effects of vitamins K and their actions on gene expression. Hepatology 1995; 22:876-882.
11. Otsuka M, Kato N, Shao BX, Hoshida Y, Ijichi H, Koike Y, et al: Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004; 40:243-251.
12. Olson RE: Osteoporosis and vitamin K intake. Am J Clin Nutr 2000; 71:1031-1042.
13. Shiraki M, Shiraki Y, Aoki C, Miura M: Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J Bone Miner Res 2000; 15:515-521.
14. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28:751-755.
15. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003; 38:207-215.
16. Sasaki I, Hashimoto S, Yoda M, Hida T, Osawa S, Nakajo S, et al: Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cells. Biochem. Biophys Res Commun 1994; 205:1305-1310.
17. Nishimaki J, Miyazawa K, Yamaguchi M, Katagiri T, Kawanishi Y, Toyama K, et al: Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic formation. Leukemia 1999; 13:1399-1405.
18. Takami A, Nakao S, Ontachi Y, Yamauchi H, Matsuda T: Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol 1999; 69:24-26.
19. Habu D, Shiomi S, Tamori A, Takeda T, Tanaka T, Kubo S, et al: Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. JAMA 2004; 292:358-361.
20. Koda M, Ueki M, Maeda Y, et al: The influence on liver parenchymal function and complications of radiofrequency ablation or the combination with transcatheter arterial embolization for hepatocellular carcinoma. Hepatol Res 2004; 29:18-23.
21. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
22. The Cancer of the Liver Italian Program (CLIP) Investigators: Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 2000; 31:840-845.